Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;17(11):1381-5.
doi: 10.1038/ejhg.2009.60. Epub 2009 Apr 15.

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

D Gareth R Evans  1 , Richard Clayton, Paul Donnai, Andrew Shenton, Fiona Lalloo
Affiliations

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

D Gareth R Evans et al. Eur J Hum Genet. 2009 Nov.

Abstract

Risk-reducing salpingo-oophorectomy is currently advocated for the reduction of both breast and ovarian cancer risk in BRCA1/2 carriers, but residual risk of peritoneal primary cancer remains a concern. A sequential series of women attending a single institution for ovarian risk management underwent either risk-reducing surgery or screening. A person-years at risk analysis was used to compare observed versus expected cancers. In total, 300 women underwent risk-reducing salpingo-oophorectomy, including 160 BRCA1/2 mutation carriers. Three occult ovarian cancers were detected at surgery. There have been 2400.4 years of follow-up and 15.79 expected cancers. No peritoneal cancers have occurred. Amongst 503 women controls with 3444.3 years of follow-up, 15.93 ovarian cancers were expected and 17 were found. There were six ovarian cancer-related deaths in the control group compared with one in the surgery group. Risk-reducing salpingo-oophorectomy in a single institution has so far avoided peritoneal cancer incidence.

PubMed Disclaimer

References

    1. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancersResults of two prospective randomised trials. N Engl J Med 19903221021–1027. - PubMed
    1. Evans DGR.Risk estimation in ovarian cancerin Lalloo F, Kerr B, Friedman J, Evans DGR (eds): Risk Assessment and Management in Cancer Genetics Oxford University Press, Oxford; 200573–82.
    1. Chappius PO, Foulkes WD.Overview of the clinical genetics of ovarian cancerin Morrison PJ, Hodgson SV, Haites NE (eds): Familial Breast and Ovarian Cancer: Genetics, Screening and Management Cambridge University Press, Cambridge; 200243–72.
    1. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk associated with ovarian cancer. Br J Obstet Gynaecol. 1998;105:493–499. - PubMed
    1. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694–1706. - PubMed